Omicron mutations, while impacting Spike substantially, have minimal impact (~2%) on the T Cell Epitope (TCE) sequences included within Gritstone’s COVID-19 vaccines (CORAL program)
T cell immunity against conserved non-Spike epitopes may offer clinical benefit
Gritstone-sponsored, CEPI-funded Phase 1 study of Spike (Beta variant) plus novel TCE constructs expected to initiate in South Africa by year end
Initial Phase 1 data from Gritstone-sponsored UK study expected early in the first quarter of 2022
https://finance.yahoo.com/news/omicron-variant-sars-cov-2-120000644.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.